Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Status:
Completed
Trial end date:
2016-07-16
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well brivanib alaninate works in treating patients with
endometrial cancer that has come back (recurred) or is persistent. Brivanib alaninate may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the tumor.